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ABSTRACT 
Type 2 diabetes (T2D) is a metabolic disease charac- 
terized by chronic hyperglycaemia due to a combina- 
tion of resistance to insulin action and an inadequate 
compensatory insulin secretory response. Chronic 
hyperglycemia is associated with long-term micro- 
and macrovascular complications leading to dysfunc- 
tion of several organs including kidney, heart, eye 
and nervous system. Early identification of chronic 
diabetic complications is necessary in order to pre- 
vent dysfunction and failure of these different organs. 
MicroRNAs (or miRNAs) are small endogenous RNAs, 
which negatively regulate gene expression. Recently, 
it has been demonstrated that miRNAs can be se- 
creted by cells, thus being detectable in serum and in 
other biological fluids. Circulating microRNAs have 
been proposed as possible biomarkers of several dis- 
eases. Here, we performed a miRNAs expression pro- 
filing in the sera of T2D patients with or without 
vascular complications in order to find specific bio- 
markers to characterize T2D complications. We ana- 
lyzed the expression of 384 microRNAs in serum 
pools from 3 groups of T2D patients: 12 T2D patients 
without any chronic complications, 12 T2D patients 
with macrovascular complications and 12 with mi- 
crovascular complications. We found 223 miRNAs 
expressed in T2D, 224 in T2D with microvascular and 
221 in T2D with macrovascular complications. Among 
expressed microRNAs, 45 resulted upregulated and 
23 downregulated in microvascular patients sera, 
while 13 upregulated and 41 downregulated in ma- 
crovascular T2D patients compared to those without 
complications. We focused and validated microRNA 
miR-31 expression in single sera from each group, 
which resulted significantly upregulated in patients 
with microvascular complications and may be indeed 
related to the presence of microangiopathy. In con- 
clusion, our study has identified miR-31 as a promis- 
ing biomarker for diabetic microvascular complica- 
tions; further prospective studies in the clinical set- 
ting are however required to establish the real util- 
ity of measuring serum circulating levels of this mi- 
croRNA.  
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1. INTRODUCTION 
Type 2 Diabetes (T2D) is a chronic metabolic disease, 
characterized by a combination of resistance to insulin 
action and of an inadequate compensatory insulin secre- 
tory response, resulting in chronic hyperglycaemia. Most 
patients with this form of diabetes are obese or have an 
increased percentage of body fat distributed predomi- 
nantly in the abdominal region; both of these conditions 
are causes of some degree of insulin resistance [1-3]. 
Type 2 Diabetes may remain undiagnosed for many years 
because of the gradually developing hyperglycaemia and 
at the time of diagnosis chronic diabetic complications 
can already be present [4,5]. Classically, long-term com- 
plications of diabetes are divided into macrovascular 
(coronary artery disease, peripheral vascular disease and 
cerebrovascular disease) and microvascular complications *GS and LN share the first co-authorship. 
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(diabetic nephropathy, neuropathy and retinopathy) and 
represent, with direct and indirect effects of chronic hy- 
perglycaemia on vascular vessels, the major source of 
morbidity and mortality in T2D [6]. Therefore, predic- 
tion and prevention of chronic diabetic complications 
represent two major objectives necessary to improve the 
quality of life of T2D patients. Thus, to date, specific 
biomarkers are needed for prediction, diagnosis and mo- 
nitoring of above mentioned complications. Recently, 
microRNAs (miRNAs) received great attention as new 
potential biomarkers in several diseases. MicroRNAs are 
small endogenous RNAs, which negatively regulate gene 
expression through their binding to the 3’UTR (3’Un- 
Translated Region) of specific mRNA targets [7]. Due to 
their inhibitory function, miRNAs may negatively regu- 
late many genes and, therefore, they are involved in sev- 
eral biological processes such as apoptosis, cell differen- 
tiation or immune function [8]. Interestingly, it has been 
demonstrated that miRNAs can be secreted by cells, via 
different pathways, and a significant number of them are 
indeed detectable in biological fluids, including serum 
[9].  
Compared to other biomarkers, miRNAs are less com- 
plex, very stable in biological fluids and conserved 
among different species. Moreover, the expression of 
some miRNAs is restricted to specific tissues leading to a 
much lower complexity and simpler targeting.  
Many studies evaluated the expression of miRNAs in 
serum/plasma from patients affected by several diseases 
and some of them were successful in identifying poten- 
tial miRNAs directly related to the disorder. Interestingly, 
circulating miRNAs can display unique expression pro- 
files related to several characteristics or to the presence 
or not of the disease. An example of this includes the 
association of miR-499 with myocardial infarction, miR- 
122 with liver injury or miR-141 with prostate cancer 
[9-11].  
In T2D, circulating miRNAs have been investigated in 
two studies, which focused on miRNAs expression pro- 
file differences in serum/plasma between T2D patients 
and control groups [10,11].  
Interestingly, both studies found several microRNAs 
differentially expressed in T2D patients plasma com- 
pared to control subjects, pointing out the potentiality of 
circulating miRNAs as biomarkers also in T2D [12,13].  
In the present study we analyzed serum miRNAs ex- 
pression profile in three groups of T2D patients: 1) T2D 
patients without any clinical, biochemical and/or instru- 
mental evidence of diabetic chronic complications; 2) 
T2D patients with macrovascular complications and 3) 
T2D patients with microvascular complications. Results 
uncovered a specific and significant hyperexpression of 
microRNA miR-31 in T2D patients with microvascular 
complications. Of note, this microRNA was previously 
reported to be hyperexpressed in retinal endothelial cells 
from diabetic rats. 
2. MATERIALS AND METHODS 
2.1. Study Population 
The study population consisted of 36 Caucasian patients 
with type 2 diabetes, who referred to the Diabetes Unit at 
University of Siena, Italy. Exclusion criteria were the 
presence of a concomitant autoimmune disease or of a 
neoplastic disease. Patients were divided into 3 groups: 1) 
12 patients without any clinical, biochemical and/or in- 
strumental evidence of diabetic chronic complications; 2) 
12 patients with diabetic macrovascular complications 
(cardiovascular or cerebrovascular or peripheral vascu- 
lar); 3) 12 subjects with diabetic microvascular compli- 
cations (retinopathy or neuropathy or nephropathy). For 
all subjects in the study, the following data were col- 
lected: age, gender, body mass index (BMI), duration of 
diabetes, presence of hypertension and/or dyslipidemia, 
glucose-, blood pressure- and lipid-lowering therapy 
(with indication of the class of drug). Table 1 shows 
main clinical parameters.  
Diabetic retinopathy was diagnosed by ophthalmologic 
 
Table 1. Main clinical parameters of study subjects. 
 
T2D w/o  
complications  




(n = 12) 
T2D with  
microvascular 
complications 
(n = 12) 
Gender (M/F) 6/6 8/4 6/6 
Age (years) 67.6 ± 4.9 67.6 ± 5.6 67.5 ± 4.5 
BMI (Kg/m2) 28.8 ± 4.7 28.9 ± 5.1 32.1 ± 8.2 
Duration of T2D 
(years) 17.6 ± 4.4 15.7 ± 6.4 15.1 ± 4.3 
HbA1c (%) 6.8 ± 0,8 7.3 ± 0.8 7.5 ± 0.9 
Triglyceride 
(mg/dl) 137.0 ± 100 127.2 ± 66.9 137.5 ± 72.0 
Total cholesterol
(mg/dl) 157.9 ± 27.3 148.0 ±23.0 174.8 ± 31.2
***
LDL cholesterol 
(mg/dl) 79.9 ± 18.2 81.3 ± 20.2 97.0 ±27.9 
HDL cholesterol 
(mg/dl) 52.7 ± 8.4 41.4 ± 12.5
* 49.9 ± 13.8 
Albuminuria 
(A/C) 0.4 ± 0.3 0.58 ± 0.53 4.3 ± 8.2
** 
eGFR-MDRD 
(ml/min/1.73 m2) 85.3 ± 17.8 80.4 ± 17.2 72.0 ± 21.0 
eGFR-CDK-EPI
(ml/min/1.73 m2) 84.8 ± 12.7 80.0 ±12.6 73.7 ± 20.7 
*T2D with macrovascular complications vs T2D without complications (p = 
0.019); **T2D with microvascular complications vs T2D without complica- 
tions (p = 0.017); ***T2D with microvascular complications vs T2D with 
macrovascular complications (p = 0.017). 
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examination with fundus oculi. Diabetic neuropathy was 
evaluated on the basis of characteristic symptoms, al- 
tered vibratory sensibility (evaluated by biothesiometer), 
altered protective sensibility (evaluated by monofilament 
of Semmes-Weinstein), alteration of tendon reflexes 
(patellar and achilles), electroneugraphic alterations. Dia- 
betic nephropathy was diagnosed by the concomitant 
presence of albuminuria, reduction of glomerular filtra- 
tion rate and hypertension. Cardiovascular disease was 
defined as positive electrocardiogram in accordance with 
Minnesota codex, positive exercise testing, positive coro- 
nary examination, or according to documented myocar- 
dial infarction. Cerebrovascular disease was defined ac- 
cording to documented ischemic brain injury or transient 
ischemic attack, while diagnosis of peripheral vascular 
disease was based on lower extremity arterial Doppler or 
on documented revascularization surgery.  
2.2. Serum Collection and RNA Extraction  
The serum fraction of each sample from T2D subjects 
was collected starting from 6 - 10 ml of entire blood. 
Serum was prepared by leaving the blood at room tem- 
perature for maximum 2 hours and then centrifuged. The 
supernatant was collected and immediately stored at 
−80˚C pending for RNA extraction. For initial miRNA 
expression profiling, we used 3 pools of serum obtained 
from 12 patients for each group.  
Total RNA from 200ul of either pooled or single sera, 
was extracted using miRNeasy kit (Qiagen, Valencia, 
CA) with some modifications. Briefly, 5 volumes of 
Trizol LS Reagent (Ambion, Austin, TX) were added to 
200 ul of serum together with 25 pM of the spike-in 
miRNA ath-miR-159 (Ambion). Phenol-chloroform se- 
paration followed by on-column RNA extraction was 
performed as specified by manufacturer’s instructions. 
Total RNA was eluted in 30ul of nuclease-free water and 
then subjected to downstream reactions.  
2.3. MiRNA Expression Profiling 
Serum miRNAs expression profiling was performed us- 
ing Taqman Human MicroRNA Array Cards Panel A 
v2.1 (Applied Biosystem, Foster City, CA) which al- 
lowed to evaluate the expression of 384 microRNAs. 
MiRNAs were reverse-transcribed using Megaplex Hu- 
man microRNA RT primers pools v2.1 and then pre- 
amplified. Briefly, 5 ul of RNA was used for each reac- 
tion adding 1.33 ul of 10X Megaplex human microRNAs 
RT primers pool A v2.1, 0.33 ul of 100 mM dNTPs, 1.33 
ul of 10X RT Buffer, 1.50 ul of 25 mM MgCl2, 0.17 ul of 
20 U/ul RNAse Inhibitor, 2.50 ul of 50 U/ul Multiscribe 
Reverse Transcriptase and 0.33 ul H2O (all from Applied 
Biosystem). The reaction was then incubated for 40 cy-  
cles at [16˚C × 2 min, 42˚C × 1 min, 50˚C × 1 sec] and 
then at 85˚C × 5 min. cDNA was then pre-amplified us- 
ing 4.16 ul of final RT reaction volume by adding 20.8 ul 
of 2X Taqman Preamp Master mix, 4.16 ul of 10X 
Taqman Human Preamp primers pool v2.1 and 12.5 ul of 
H2O (all from Applied Biosystem). The reaction was 
then incubated 95˚C × 10 min, 55˚C × 2 min, 72˚C × 2 
min, 12 cycles at [95˚C × 15 sec, 60˚C × 4 min] and fi- 
nally 99.9˚C × 10 min. Preamplification reaction was 
diluted 1:4 in Tris-EDTA buffer pH 8.0 and 100 ul were 
loaded in Taqman Human MicroRNA Array Cards fol- 
lowing manufacturer instructions.  
For single assay miRNAs evaluation in each serum, 
2.5 ul of preamplification product were used in Real 
Time PCR reaction for each microRNA analyzed. VIIA7 
Real Time PCR instrument (Applied Biosystem) was 
used to perform Array cards or single assay reactions.   
2.4. Data and Statistical Analysis  
Data from Taqman Human MicroRNA Array Cards were 
exported using ViiA7 RUO software and then analyzed 
using Expression Suite software v1.0.1 (Applied Biosys- 
tem). Data normalization was performed using 4 differ- 
ent housekeeping microRNAs: ath-miR-159 (spike-in), 
RNAU6, hsa-miR-16 and hsa-miR-451. Only miRNAs 
with Ct < 35 and with a high efficiency amplification 
plot were taken into consideration for subsequent analy- 
sis. Data were further analyzed using 2−ddCt method and 
differentially expressed miRNAs were identified using a 
fold change cutoff <0.35 (downregulation) and >2.5 
(upregulation). Graphical analysis for Hierarchycal clus- 
tering was performed using Spotfire software v5.0 
(Tibco). Data from single assay miRNAs in single serum 
were normalized using ath-miR-159 and hsa-miR-16 and 
analyzed using 2−dCt method. Non-parametrical Mann- 
Whitney U test was performed to evaluate significance 
(p-value < 0.05) of differentially expressed miRNAs or 
of clinical parameters. 
3. RESULTS 
3.1. MiRNAs Expression Profile in Sera from 
T2D Patients  
We analyzed the expression of 384 microRNAs (381 
single miRNAs + 3 miRNAs repeated for stability con- 
trol) using Human Taqman array Card A v2.1, in total- 
RNA extracted from 12 pooled sera derived from T2D 
patients without complications, 12 from T2D with ma- 
crovascular complications and 12 from T2D with mi- 
crovascular complications.  
Among the 381 miRNAs analyzed, we considered as 
expressed those with a Ct value < 35 and with a valid 
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amplification plot. On this basis, we detected 223 
miRNAs expressed in T2D patients without complica- 
tions, 221 in T2D with macrovascular complications and 
224 in T2D with microvascular complications.  
We used four different housekeeping small RNAs/ 
miRNAs (ath-miR-159, miR-16, miR-451, U6) to nor- 
malize overall miRNA expression; all four resulted 
stably expressed in all samples analyzed.  
MicroRNA miR-223 resulted as the most expressed 
miRNA in serum from all three groups of patients ana- 
lyzed (Figure 1), followed by miR-19b and by miR-451.  
As demonstrated by hierarchical clustering/heat map 
analysis (Figure 1), a differential miRNA expression 
was detected among the three groups of samples. More 
specifically, in comparison with T2D patients without 
complications, we detected 54 differentially expressed 
miRNAs (13 upregulated and 41 downregulated) in T2D 
patients with macrovascular and 68 (45 upregulated and  
23 downregulated) in T2D subjects with microvascular 
complications.  
3.2. Increased Expression Levels of miR-31 in 
Sera from T2D Patients with Microvascular 
Complications  
Among differentially expressed miRNAs, we identified 
miR-31 as the most upregulated miRNA in serum of 
T2D patients with chronic complications compared to 
T2D without. As shown by hierarchical clustering analy- 
sis (Figure 1 right panel), we found little or no expres- 
sion of miR-31 in serum of T2D patients without com- 
plications, in contrast to high levels detectable in ma- 
crovascular and in microvascular T2D patient sera  
Moreover, we found that miR-31 resulted overex- 
pressed in serum of T2D patients with microvascular vs 




Figure 1. Hierarchical clustering analysis of miRNA expression profiling. MicroRNAs expressed in the 3 groups analyzed (T2D = 
Type 2 Diabetes without complications; T2D MA = Type 2 Diabetes with macrovascular complications; T2D MI = Type 2 Diabetes 
with microvascular complications) are reported in the hierarchical clustering heatmap analysis in which each row represents a 
miRNA. The scale color from blue (high expression) to red (low expression) reports the expression levels of each microRNA. On the 
right side, high magnification of the heatmap shows a graph zone reporting miR-31 differential expression, whose clustering node is 
indicated by the green arrow (left side dendogram).    
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Interestingly, we observed that miR-31 was the unique 
miRNA, among those analyzed, which clustered alone 
with a high hierarchy node (Figure 1 green arrow).  
Using correlation analysis, we plotted miRNA expres- 
sion values to determine the level of correlation between 
the 3 groups of patients analyzed. As shown in Figures 
2(a)-(c), we detected a significant correlation (R > 0.90, 
Spearman R correlation test) for the three comparisons; a 
better correlation was shown between T2D with mi- 
crovascular complications vs T2D with macrovascular 
complications (Figure 2(c)). MicroRNA miR-31 (Figure 
2 indicated by the arrow) was located far from the ideal 
correlation fitting line both in T2D without complica- 
tions vs T2D with macrovascular (Figure 2(a)) or with 
microvascular complications (Figure 2(b)).  
In the light of the interesting miR-31 expression pat- 
tern, we decided to further analyze its expression by Real 
Time PCR single assay, in sera from all patients. Indeed, 
we confirmed that miR-31 was upregulated in serum of 
T2D patients with microvascular complications vs T2D 
without complications (p = 0.03) and vs T2D individuals 
with macroangiopathy (p = 0.04). No significant miR-31 
upregulation was observed in T2D patients with ma- 
crovascular complications vs uncomplicated T2D (Fig- 
ure 3).  
4. DISCUSSION 
Vascular complications represent the major cause of 
morbidity and mortality in T2D. Of note, major chronic 
complications may already be present at the time of dis- 
ease diagnosis, due to the gradual development of hyper- 
glycaemia in the disease natural history. Adequate early 
detection of diabetic complications may help to prevent 
many of detrimental effects caused by vasculopathy. 
Currently, there are no good soluble biomarkers to spe-  
cifically detect vascular damage in diabetes. Therefore, 
search for new biomarkers is necessary in order to im- 
prove prediction, diagnosis and monitoring of diabetic 
complications. MicroRNAs may represent ideal candi- 
dates as new biomarkers for several diseases. Indeed, 
recent findings indicate that miRNAs can be secreted by 
cells and, therefore, can be found in biological fluids. 
Serum circulating miRNAs are becoming widely used to 
predict or follow-up several disorders (e.g. cancer). In- 
deed, they are relatively stable in biological fluids, and 
easily measurable, thanks to newly available expression 
profiling platforms. Moreover, some miRNAs have been 
shown to be highly tissue- and/or disease-specific, thus 
representing potentially valuable sensors of diseased 
cells/tissues.  
Here, we aimed to detect differentially expressed 
miRNAs in serum of T2D patients without and with 
vascular chronic complications, in order to identify po- 
tentially usable biomarkers associated with diabetic mi- 
cro- or macro-angiopathy. We initially performed an ex- 
tensive miRNAs expression profiling using pooled sera 
from each group.  
We detected a similar number of miRNAs expressed 
among the three groups of samples. As quality and con- 
cordance control we detected miR-223 as the most ex- 
pressed miRNA in serum of all three groups of patients 
analyzed, without any differential expression among 
such groups. These results are in agreement with those 
reported by Wang et al., who analyzed miRNA expres- 
sion profile in serum and plasma of normal control sub- 
jects using two different profiling platforms [14].  
Among differentially expressed miRNAs, we further 
studied miR-31, since this miRNA was the most differ- 
entially expressed between T2D subjects without and 
with diabetic vascular complications. To this end, miR- 
31 expression was analyzed in each serum by real-time  
 
 
(a)                                        (b)                                         (c) 
Figure 2. MicroRNA profiling correlation plot between groups of patients. (a) miRNA expression correlation plot between T2D 
without complications (x-axis) and T2D with macrovascular complications (y-axis); (b) miRNA expression correlation plot between 
T2D without complication (x-axis) and T2D with microvascular complication (y-axis); (c) miRNA expression correlation plot be- 
tween T2D with microvascular (x-axis) and macrovascular complication (y-axis). In all three panels, miR-31 is indicated by the ar- 
row. Spearman R test values are shown.   
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Figure 3. Increased expression levels of miR-31 in sera from 
T2D patients with microvascular complications. MicroRNA 
miR-31 expression was assessed in single sera using Taqman 
single assay real time PCR. The three sample groups (T2D = 
Type 2 Diabetes without complications; T2D MA = Type 2 
Diabetes with macrovascular complications; T2D MI = Type 2 
Diabetes with microvascular complications) are reported. Mi- 
croRNA miR-31 expression level is reported as 2−dCT. Mean ± 
SEM are reported for each group. Mann Whitney U test has 
been used to evaluate statistical significance. 
 
PCR using Taqman miRNA single assay. Indeed, miR- 
31 was significantly hyperexpressed in serum of patients 
with microvascular complications vs uncomplicated T2D 
subjects and vs T2D individuals with macrovascular 
complications. Comparison of miR-31 expression be- 
tween T2D with macrovascular and T2D without com- 
plications did not reveal any significant difference, thus 
suggesting that miR-31 upregulation may be specifically 
related to microvascular complications. This is the first 
report to uncover miR-31 serum levels as a potential 
biomarker of diabetic microangiopathy in man. It is pos- 
sible to speculate that increased miR-31 levels in serum 
from T2D subjects with microangiopathy may reflect 
phenomena occurring at endothelial cell level. This is 
supported by the observation of increased miR-31 ex- 
pression in retinal endothelial cells (RECs) and in total 
retina of streptozotocin-induced diabetic rats, 3 months 
after diabetes onset [15].  
Vascular endothelial cells may play a critical role in 
the establishment of microvascular complications in T2D 
[16,17]. Inflammatory cytokines in T2D strongly con- 
tribute to microvascular damage. Specifically, systemic 
TNF-alpha resulted increased in T2D patients and di- 
rectly correlated with microvascular complications [18, 
19]. Recently, Suarez et al. demonstrated the effects of 
TNF-alpha on miRNAs expression in endothelial cell 
line HUVEC, uncovering increased miR-31 expression 
in response to TNF-alpha as a possible mechanism to 
control inflammation through reduction of E-Selectin 
(involved in leukostasis), which is specifically controlled 
by miR-31 itself. The same authors found that miR-31 is 
one of the VEGF responsive miRNAs and therefore 
could be involved in vascular remodeling secondary to 
inflammatory insults [20]. Of note, miR-31 target genes 
include E-selectin (involved in leukostasis-experiment- 
tally validated), integrin-alpha5 (involved in angiogene- 
sis-experimentally validated) and NOS1 (oxidative stress- 
predicted using Targetscan 6.2) [20].  
Overall, upregulation of miR-31 may have inhibitory 
functions on leukostasis, vascular permeability and an- 
giogenesis, thus reflecting a response of endothelial cells 
to diabetes-induced damage. It is possible to hypothesize 
that miR-31 increased expression levels in serum of T2D 
patients with microvascular complications may therefore 
derive from endothelial cells, by shedding vesicles or 
apoptotic bodies containing miR-31.  
In conclusion, our study has identified miR-31 as a 
promising biomarker for diabetic microvascular compli- 
cations; further prospective studies in the clinical setting 
are however required to establish the real utility of meas- 
uring circulating serum levels of this microRNA.  
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